Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

NCT02856568 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Site dropped study

Conditions

Non-Resectable Cholangiocarcinoma
Recurrent Cholangiocarcinoma
Stage III Extrahepatic Bile Duct Cancer
Stage III Intrahepatic Cholangiocarcinoma
Stage IIIA Hilar Cholangiocarcinoma
Stage IIIB Hilar Cholangiocarcinoma
Stage IVA Extrahepatic Bile Duct Cancer
Stage IVA Hilar Cholangiocarcinoma
Stage IVA Intrahepatic Cholangiocarcinoma
Stage IVB Extrahepatic Bile Duct Cancer
Stage IVB Hilar Cholangiocarcinoma
Stage IVB Intrahepatic Cholangiocarcinoma
Unresectable Extrahepatic Bile Duct Carcinoma

Interventions

DRUG: Cisplatin
DRUG: Gemcitabine Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Ricolinostat

Sponsor

Mayo Clinic

Collaborators

[object Object]